LO-CD 2a强烈抑制混合淋巴细胞培养(MLC)3并诱导T细胞凋亡。此外,LO-CD 2a不诱导静息T细胞的增殖,并且抑制由OKT 3抗体诱导的T细胞增殖,诱导非常低水平的细胞因子释放,并且还抑制由OKT 3诱导的细胞因子产生。LO-CD 2a强烈抑制用可溶性OKT 3刺激的外周血单核细胞的增殖,并且诱导人T细胞低反应性。将LO-CD 2a添加至原代MLC抑制T细胞增殖应答,并对继发性免疫应答具有后续抑制作用,从而阻断原代和记忆性同种异体抗原增殖应答。二次MLC中的人T细胞低反应性仅限于同种异体抗原,并且在不存在抗体的情况下和在细胞表面重新表达CD 2之后都发生 抗人CD 2(LO-CD 2a)体内抗体原液该产品同种型对照:Rat IgG2b In Vivo Isotype Control - Low Endotoxin [1-2] (ICH2243) 缓冲液:ICH3001-100ml,nICH3002-100ml,nICH3003-100ml, 浓度:≥ 2.0 mg/ml 纯度:>95% by SDS-PAGE 内毒素:<1.0 EU/mg as determined by the LAL method 制剂:Sterile, preservative-free, solution in PBS. BSA and Azide free.
应用类型
ELISA, Functional Assays, Flow Cytometry
免疫原
LO-CD2a was developed as an immunosuppressive agent for use in organ allotransplantation. LO-CD2a was produced by immunizing a LOU/C rat with purified human T lymphocytes and fusing the splenocytes with the non-secreting rat fusion cell line IR983F, resulting in a rat IgG2b mAb of the IgK-1a allotype